[SY9-3] Progress and challenges for immune checkpoint blockade in hematologic malignancies
Alexander M. Lesokhin, MD, is an Assistant Attending Physician on Myeloma Service and Immunotherapeutics Core and a member of the Ludwig Collaborative laboratory at Memorial Sloan Kettering Cancer Center in New York, New York. He received his MD from the Albert Einstein College of Medicine with distinction in research.Dr. Lesokhin’s research focuses on the ability of cancers to evade the immune system and on developing novel treatments to reverse this process. He leads a portfolio of clinical trials testing the clinical and immune effects of antibodies targeting immune checkpoints, bi-specific engagers, and cellular therapies. He has additionally developed and validated assays for measuring myeloid-derived suppressor cells (MDSC) as a potential biomarker for efficacy of immune based therapies. His work has resulted in >50 peer-reviewed publications. Dr. Lesokhin has received career development awards from the American Cancer Society and the Melanoma Research Alliance and receives additional funding from Cycle for Survival, the Sawiris Foundation, and the Parker Institute for Cancer Immunotherapy.
抄録パスワード認証
抄録の閲覧にはパスワードが必要です。パスワードを入力して認証してください。パスワードは「第81回日本血液学会学術集会 ポケットプログラムのプログラム検索・スケジュール登録アプリのご案内ページ」に記載してあります。